Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PBLS – Parabilis Medicines Inc

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=PBLS#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
PBLS — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

4.44

Margin Of Safety %

Put/Call OI Ratio

0.64

EPS Next Q Diff

EPS Last/This Y

0.15

EPS This/Next Y

-0.24

Price

34.83

Target Price

41.75

Analyst Recom

1

Performance Q

Upside

N/A

Beta

Ticker: PBLS




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-07-14PBLS31.15N/AN/A0
2026-07-15PBLS29.91N/AN/A0
2026-07-16PBLS29.03N/AN/A0
2026-07-17PBLS29.84N/AN/A0
2026-07-20PBLS27.84N/AN/A0
2026-07-21PBLS30.02N/AN/A0
2026-07-22PBLS30.680.500.6733
2026-07-23PBLS32.870.542.0037
2026-07-24PBLS31.40.440.8036
2026-07-27PBLS31.740.440.8036
2026-07-28PBLS32.10.470.0044
2026-07-29PBLS31.880.470.0044
2026-07-30PBLS32.40.470.0044
2026-07-31PBLS34.170.450.0045
2026-08-03PBLS34.20.440.6746
2026-08-04PBLS35.990.460.0051
2026-08-05PBLS35.070.460.0051
2026-08-06PBLS35.470.44999.9952
2026-08-07PBLS34.940.640.1759
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-07-14PBLS31.06- - -
2026-07-15PBLS29.91- - -
2026-07-16PBLS28.95- - -
2026-07-17PBLS29.63- - -
2026-07-20PBLS27.29- - -
2026-07-21PBLS30.12- - -
2026-07-22PBLS30.75- - -
2026-07-23PBLS32.80- - -
2026-07-24PBLS31.31- - -
2026-07-27PBLS31.82- - -
2026-07-28PBLS32.10- - -
2026-07-29PBLS31.60- - -
2026-07-30PBLS32.15- - -
2026-07-31PBLS33.99- - -1.66
2026-08-03PBLS34.08- - -1.66
2026-08-04PBLS34.08- - -1.66
2026-08-05PBLS34.90- - -1.66
2026-08-06PBLS35.59- - -1.66
2026-08-07PBLS34.83- - -1.66
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




16 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-07-14PBLS294.70102.463.11
2026-07-15PBLS294.70102.463.11
2026-07-16PBLS294.70102.463.11
2026-07-17PBLS294.70102.463.11
2026-07-20PBLS294.7042.793.11
2026-07-21PBLS294.7042.793.11
2026-07-22PBLS294.7042.793.11
2026-07-23PBLS308.2542.793.11
2026-07-24PBLS308.2542.793.11
2026-07-27PBLS308.2548.494.44
2026-07-28PBLS308.2548.494.44
2026-07-29PBLS308.2948.494.44
2026-07-30PBLS308.2948.494.44
2026-07-31PBLS308.3048.494.44
2026-08-03PBLS308.3049.374.44
2026-08-04PBLS308.3049.374.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
16 items Current Page1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=PBLS 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.37

Insider Transactions

308.3

Institutional Transactions

49.37

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

9

Growth Score

Sentiment Score

93

Actual DrawDown %

5.4

Max Drawdown 5-Year %

Target Price

41.75

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

-1.66

EPS Next Y. (Est.)

-1.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.43

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-97.1

EPS 1 7Days Diff

-1.7

EPS 1 30Days Diff

-1.66

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=PBLS 589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=PBLS 589 450 ]
PBLS — P/E HistoricalBiotechnology
Parabilis Medicines, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 145
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
PBLS

Latest News

Caricamento notizie per PBLS
stock quote shares PBLS – Parabilis Medicines Inc Stock Price stock today
news today PBLS – Parabilis Medicines Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PBLS – Parabilis Medicines Inc yahoo finance google finance
stock history PBLS – Parabilis Medicines Inc invest stock market
stock prices PBLS premarket after hours
ticker PBLS fair value insiders trading